Dual effect of a new compound, rupatadine, on edema induced by platelet-activating factor and histamine in dogs: Comparison with antihistamines and PAF antagonists

Drug Development Research

Volumn 39, Issue 1, 1996, Pages 12-18

  Queralt, Mireia ^a   Merlos, Manuel ^b   Cirai, Marta ^b   Puigdemont, Anna ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Grupo Uriach   (Spain)

Author keywords

Edema; Histamine; PAF; Rupatadine

Indexed keywords

1 ACETYL 4 (8 CHLORO 5,6 DIHYDRO 11H BENZO[5,6]CYCLOHEPTA[1,2 B]PYRIDIN 11 YLIDENE)PIPERIDINE; ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; APAFANT; CETIRIZINE; FOROPAFANT; HISTAMINE; LEVOCABASTINE; LORATADINE; RUPATADINE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EDEMA; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; URTICARIA;

EID: 0030497903     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(19960901)39:1<12::AID-DDR2>3.0.CO;2-N     Document Type: Article

References (31)

1. 1 antihistamines. Ann Allergy 67:541-547.
2. 1- antagonists on PAF-acether-induced inflammatory responses in the skin of experimental animals and man. Br J Pharmacol 85:109-113.
3. Awouters F, Vermeire J, Smeyers F, Vermote P, Van Beek R, Niemegeers C (1986): Oral antiallergic activity in ascaris hypersensitive dogs: a study of known antihistamines and of the new compounds ramastine (R 57 959) and levocabastine (R 50 547). Drug Dev Res 8:95-102.
4. 1 antihistamines. In New Perspectives in Histamine Research. Basel: Birkhäuser Verlzg, pp. 181-195.
5. Billah MM, Chapman RW, Egan RW, Gilchrest H, Piwinski JJ, Sherwood J, Siegel MI, West RE, Jr, Kreutner W (1990): Sch 37370: A potent, orally active, dual antagonist of platelet-activating factor and histamine. J Pharmacol Exp Ther 245:471-478.
6. Camussi G, Anglietta M, Coda R, Bussolino F, Piacibello W, Tetta C (1981): Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. Immunology 42:191-199.
7. Carceller E, Merlos M, Girai M, Balsa D, Almansa C, Bartroli J, Garcia-Rafanell J, Forn J (1994): [(3-Pyridyl alkyl)piperidylidene] benzocycloheptapyridine derivatives as dual antagonists of PAF and histamine. J Med Chem 37:2697-2703.
8. Church MK (1992): Anti-allergy drugs. In Barnes PJ (eds): New Drugs for Asthma. Oxford: Information Press, vol 2, pp 135-163.
9. Clissold SP, Skorin EM, Goa KL (1989): Loratadine a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 37:42-57.
10. Eda R, Sugiyama H, Hopp RJ, Bewtra AK, Townley RG (1993): Effect of loratadine on human eosinophil function in vitro. Ann Allergy 71:373-378.
11. Eiser NM (1982): Histamine antagonists and asthma. Pharmacol Ther 17:239-250.
12. Fadel R, David B, Herpin-Richard N, Borgnon A, Rassemont R, Rihoux JP (1990): In vivo effects of cetirizine on cutaneous reactivity and eosinophil migration induced by platelet activating factor (PAF-acether) in man. J Allergy Clin Immunol 86:314-320.
13. Fjellner B, Hagermark O (1985): Experimental pruritus evoked by platelet activating factor (PAF-acether) in human skin. Acta Derm Venereol (Stockh) 65:409-412.
14. Guinot P, Braquet P, Duchier J, Cournot A (1986): Inhibition of PAF-acether induced wheal and flare reaction in man by specific PAF antagonist. Prostaglandins 32:160-163.
15. Herbert JM, Laplace MC, Bernat A, Salel V, Maffrand JP (1992): Effect of SR27417 on oedema formation induced in rabbit skin by platelet-activating factor or antigen. Eur J Pharmacol 216: 175-181.
16. Lai CKW, Oilier S, Lau CK, Holgate ST (1991): Effect of axelastine and ketotifen on the bronchial and skin responses to platelet-activating factor in humans. Clin Exp Allergy 21:489-496.
17. Mclntyre TM, Zimmermann GA, Satoh K, Prescott SM (1985): Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradkykinin and adenosine. J Clin Invest 76:271-280.
18. Morley J, PageCP, Mazzoni L, Sanjar S (1986): Effects of ketotifen upon responses to platelet activating factor: a basis for asthma prophylaxis. Ann Allergy 56:335-340.
19. Nimmo Wilkie JS, Yager JA, Eyre P, Parker WM (1990): Morphometric analyses of the skin of dogs with atopic dermatitis and correlations with cutaneous and plasma histamine and total serum IgE. Vet Pathol 27:179-186.
20. Petrolani M, Ferrer-Lopez P, Vargaftig BB (1989): From antiasthma drugs to PAF-acether antagonism and back. Present status. Biochem Pharmacol 38:1373-1384.
21. Sciberras DG, Bologese JA, Goldenberg MM, James I, Baber NS (1988): Platelet-activating factor induced inflammatory responses in the skin. Prostaglandins 35:833.
22. Sciberras DC, Jordan S, Gill D, Baber NS, James I (1991): The role of histamine in acute inflammatory responses to intradermal platelet activating factor. Br J Clin Pharmacol 32:85-90.
23. 1-receptor antagonists. Clinical pharmacology and therapeutics. J Allergy Clin Immunol 30:899-914.
24. 1-receptor antagonist treatment. J Allergy Clin Immunol 86:995-999.
25. 1receptor antagonists). J Allergy Clin Immunol 90:705-715.
26. 1-receptor antagonist therapy. Clin Pharmacokinet 21(5):372-393.
27. 1-receptor-antagonist drugs. N Engl J Med 330:1663-1670.
28. Sipka S, Koltai M, Braquet P, Szegedi G (1992): Histamine potentiates human platelet aggregation induced by platelet-activating factor. Int Arch Allergy Appl Immunol 97:89-92.
29. Spencer CM, Faulds D, Peters DH (1993): Cetrizine. A reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs 46(6):1055-1080.
30. Szabo C, Wu Ch, Mitchell JA, Gross SS, Thimermann Ch, Vane JR (1993): Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ Res 73:991-999.
31. 1 effects of second-generation antihistamines. Ann Allergy 68:190-196.